Alterome Therapeutics Launches With $64M Series A Financing

SAN DIEGO–(BUSINESS WIRE)–Alterome Therapeutics, Inc., a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer, announced the closing of a $64M Series A financing. The financing was led by OrbiMed, with participation from Nextech Invest, Vida Ventures, Boxer Capital, and others. Alterome Therapeutics was co-founded by Eric Murphy, Ph.D., and Ryan Corcoran, M.D., Ph.D. Dr. Murphy, an industry veteran with 20 years in oncology research and drug
Click here to view original post